Results 41 to 50 of about 16,360 (203)

The Impact of Environmental Pollution and Climate Change on Allergic Rhinitis and Lung Diseases

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Environmental pollution and climate change seriously affect human health, leading to the onset and exacerbation of chronic respiratory diseases, such as allergic rhinitis and lung diseases. Over the past several decades, increasing air pollution and environmental exposure owing to global urbanization, industrialization, and rapid economic ...
Xin‐Yan Liu   +4 more
wiley   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

open access: yesAllergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi   +21 more
wiley   +1 more source

CHRONIC NASAL HYPER-REACTIVITY (CURRENT CLASSIFICATIONS, CLINICAL PATTERN, DIAGNOSIS)

open access: yesМедицинский совет, 2017
Nasal hyper-reactivity (NG) is a clinical phenomenon manifested by increased individual sensitivity of the nasal mucosa to factors that do not cause symptoms in healthy people.
E. P. MERKULOVA, S. N. KOLESNIKOVA
doaj   +1 more source

Early-life cadmium exposure elevates susceptibility to allergic asthma in ovalbumin-sensitized and challenged mice

open access: yesEcotoxicology and Environmental Safety, 2023
Increasing evidence have demonstrated that early-life exposure to environmental toxicants elevates risk of allergic asthma. Cadmium (Cd) is widely present in the environment.
Wen-Jing Wang   +10 more
doaj   +1 more source

Intranasal cold dry air is superior to histamine challenge in determining the presence and degree of nasal hyperreactivity in nonallergic noninfectious perennial rhinitis [PDF]

open access: yes, 1998
The objective of the study was to compare cold dry air (CDA) and histamine in differentiating patients with nonallergic noninfectious perennial rhinitis (NANIPER) from control subjects.
Braat, J.P. (Joseph)   +4 more
core   +2 more sources

BRONCHOPROTECTIVE EFFECT OF GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

open access: yesМедицинский совет, 2017
Bronchial hyperreactivity (BHR) is one of the functional characteristics of chronic obstructive pulmonary disease (COPD) and is present in most patients with this disease.
I. N. Trofimenko   +2 more
doaj   +1 more source

Peculiarities of spirometric indices in schoolchildren with bronchial asthma, depending on their atopic status [PDF]

open access: yes, 2016
In article on based analysis of spirometric indicators was researched the peculiarities of nonspecific bronchial hyperreactivity depending on the atopic status of school-age children.
Haras, M.N.
core  

Endothelin-1 in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction [PDF]

open access: yes, 2007
Background Exercise-induced bronchoconstriction (EIB) is a highly prevalent condition, whose pathophysiology is not well understood. Endothelins are proinflammatory, profibrotic, broncho- and vasoconstrictive peptides which play an important role in the ...
Tomasiak Maria M   +3 more
core   +1 more source

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma   +9 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial (INTEGUMENT‐OLE)

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Background INTEGUMENT‐PED/NCT04845620, a 4‐week, phase 3 trial, demonstrated efficacy and safety of roflumilast cream 0.05% in children aged 2–5 years with mild‐to‐moderate atopic dermatitis (AD). A phase 3 open‐label extension trial (INTEGUMENT‐OLE [NCT04804605]) investigated long‐term outcomes continuing roflumilast cream for ≤ 56 weeks ...
Lawrence F. Eichenfield   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy